Project ECHO® is a telementoring workforce development model that targets under-resourced communities lacking access to specialty care. The model builds virtual communities of practice, including specialists and community primary care professionals (PCPs) to combat clinical inertia and health disparities. While the ECHO model has gained global recognition, implementation of the model related to diabetes is lagging compared to other specialty conditions. This review highlights diabetes-endocrine (ENDO)-focused ECHOs using data reported in the ECHO Institute’s centralized data repository (iECHO) and the learning collaborative for diabetes ECHOs. It also describes the implementation of diabetes ECHOs and their evaluation. Learner and patient-centered outcomes related to diabetes ECHOs are reviewed. Program implementation and evaluations have demonstrated utility of the ECHO model for diabetes programs to (1) address unmet needs of diabetes care in the primary care setting, (2) improve knowledge and confidence in managing complex diabetes and change provider prescribing habits, (3) improve patient outcomes, and (4) address diabetes quality improvement practices in primary care. More studies with broader collaboration among sites are needed to evaluate the model related to diabetes, especially applied to addressing therapeutic inertia, adoption of diabetes technology, and reducing health disparities.
Background Despite newer diabetes medications and technology being available, therapeutic inertia persists and there are more people living with "uncontrolled" diabetes than meeting A1c targets. Here we evaluate how the ECHO© model for diabetes management changed prescribing practices among participating primary care providers (PCPS). Methodology Three unique diabetes ECHO programs evaluated comfort or perception of prescribing practice changes for local community PCPs (n=74) in four regions (Illinois, District of Columbia, New Mexico, and Washington). One site representing two regions collected pre- and post-program participant surveys (n=45) while two sites collected post-program surveys only (n=29), in which respondents reported perceptions of changes resulting from participation in ECHO. Participants reported their use of technology (professional and personal continuous glucose monitoring (CGM) and insulin pumps) and medications (insulin and non-insulin). Results On a 4-point Likert scale, PCPs’ (n=45) average self-reported prescription use for newer diabetes medications with cardiovascular indications increased from 3.07 (sometimes) to 3.84 (sometimes-always). Presentation: Tuesday, June 14, 2022 11:00 a.m. - 11:15 a.m.
INTRODUCTION: First reported in 1973, euglycemic diabetic ketoacidosis (euDKA) historically accounted for 0.8-1.1% of diabetic ketoacidosis (DKA) cases [1]. Without hyperglycemia, the anion gap metabolic acidosis (AGMA) of euDKA may be attributed to other causes. We present a case of euDKA that was mistaken for toxic alcohol poisoning. CASE PRESENTATION:A 53-year-old woman with type 2 diabetes (T2D), for which she reported taking metformin and glyburide, presented with abdominal pain and nausea. She also reported drinking "vodka" given by a stranger the day prior. Labs included bicarbonate 12 mEq/L, anion gap (AG) 18, lactate 1.7 mmol/L, lipase 735 U/L, and urinalysis with 2þ glucose and 3þ ketones. CT confirmed pancreatitis. Correctional insulin was ordered but not given due to blood sugar of 121-225 mg/dL. Repeat labs overnight revealed bicarbonate <5, AG >18, and arterial pH 7.09. After toxicology consult, she was given IV fomepizole and transferred to the ICU for urgent hemodialysis (HD) for possible toxic alcohol poisoning. Just prior to placing HD access, records obtained revealed that she was prescribed empagliflozin. Ultimately, a toxic alcohol panel was negative and beta-hydroxybutyrate was elevated at 0.86 mmol/L. She was treated with infusions of crystalloid, insulin, and dextrose. Her ketosis resolved in 9 days, and she was discharged on insulin and metformin.DISCUSSION: Previously seen with low caloric intake, alcohol or cocaine use, liver disease, or pregnancy, euDKA has recently been linked to sodium glucose cotransporter 2 inhibitor (SGLT2I) use [2]. Since FDA approval in 2013, SGLT2I use has steadily risen as data on cardiovascular and renal benefits accumulate. SGLT2Is act independent of insulin by blocking proximal tubule reabsorption of glucose. This can lead to euglycemia despite insulin deficiency and the potential for an acute insult, like pancreatitis, to trigger euDKA. Along with lack of insulin, SGLT2I-related euDKA may be mediated by volume depletion, counterregulatory hormones, and enhanced lipolysis and fatty acid oxidation [3]. Notably, pancreatitis can trigger euDKA without SGLT2I use [2]. Though the initial ketonuria and lack of inebriation were, in retrospect, clues to the presence of DKA in this case, the report of a suspicious ingestion led to a presumptive diagnosis of toxic alcohol poisoning. Indeed, untreated toxic alcohol poisoning can lead to major disability or death, and prompt empiric treatment is vital if clinical suspicion exists. CONCLUSIONS:The rapid diagnosis of AGMA remains a challenge in intensive care. As SGLT2I use continues to grow, providers will increasingly encounter euDKA. Importantly, euglycemia does not exclude DKA, and euDKA must be routinely considered in the differential of unexplained severe AGMA to prevent adverse outcomes from delays in treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.